Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL3 | Q96JM7 | 6/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 6/20 | 0.41 |
| ▸ | MBTD1 | Q05BQ5 | 5/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | HTR6 | P50406 | 1/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.36 |
| ▸ | TP53BP1 | Q12888 | 1/20 | 0.35 |
| ▸ | L3MBTL4 | Q8NA19 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3548348 | 1.00 | L3MBTL3 (0.41) | L3MBTL3L3MBTL1MBTD1CYP2D6CYP2C19 | |
| SCHEMBL3549709 | 1.00 | L3MBTL3 (0.41) | L3MBTL3L3MBTL1MBTD1CYP2D6CYP2C19 | |
| SCHEMBL140623 | 0.97 | L3MBTL1 (0.43) | L3MBTL3L3MBTL1MBTD1CYP2D6CYP2C19 | |
| SCHEMBL1489996 | 0.92 | L3MBTL3 (0.38) | L3MBTL3L3MBTL1MBTD1CYP2D6CYP2C19 | |
| SCHEMBL1489616 | 0.85 | L3MBTL3 (0.39) | L3MBTL3L3MBTL1MBTD1CYP2D6CYP2C19 | |
| SCHEMBL1489870 | 0.85 | L3MBTL3 (0.39) | L3MBTL3L3MBTL1MBTD1CYP2D6CYP2C19 | |
| SCHEMBL1489973 | 0.85 | L3MBTL3 (0.39) | L3MBTL3L3MBTL1MBTD1CYP2D6CYP2C19 | |
| SCHEMBL337764 | 0.85 | L3MBTL1 (0.34) | L3MBTL3L3MBTL1MBTD1HTR6KDM4E | |
| SCHEMBL667548 | 0.82 | L3MBTL1 (0.40) | L3MBTL3L3MBTL1MBTD1HTR6TP53BP1 | |
| SCHEMBL477164 | 0.82 | L3MBTL1 (0.40) | L3MBTL3L3MBTL1MBTD1HTR6TP53BP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1030 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114450284-B | 6, 7-Dihydro-5H-pyrido [2,3-C ] pyridazine derivatives as BCL-XL protein inhibitors | 法国施维雅药厂 | 2024-05-07 | — | — | CN | claimed |
| US-20240115553-A1 | COMPOSITIONS AND METHODS FOR TREATING BRAIN INJURY | AZEVAN PHARMACEUTICALS, INC. (US) | 2024-04-11 | — | — | US | claimed |
| EP-4003989-B1 | 6,7-DIHYDRO-5H-PYRIDO[2,3-C]PYRIDAZINE DERIVATIVES AND RELATED COMPOUNDS AS BCL-XL PROTEIN INHIBITORS AND PRO-APOPTOTIC AGENTS FOR TREATING CANCER | SERVIER LAB (FR) | 2023-12-27 | — | — | EP | claimed |
| US-11639352-B2 | Benzothiazole compounds for the treatment of autoimmune diseases | HOFFMAN-LA ROCHE INC. (US) | 2023-05-02 | — | — | US | claimed |
| US-11591299-B1 | Prodrug compound of levosimendan, preparation method and use thereof | Beijing Chenguang Tongchuang Pharmaceutical Research Institute Co., Ltd. (CN) | 2023-02-28 | — | — | US | claimed |
| CN-112500353-B | Levosimendan prodrug compound, preparation method and application thereof | 北京晨光同创医药研究院有限公司 | 2022-11-25 | — | — | CN | claimed |
| EP-4003989-A1 | 6,7-DIHYDRO-5H-PYRIDO[2,3-C]PYRIDAZINE DERIVATIVES AND RELATED COMPOUNDS AS BCL-XL PROTEIN INHIBITORS AND PRO-APOPTOTIC AGENTS FOR TREATING CANCER | Les Laboratoires Servier (FR) | 2022-06-01 | — | — | EP | claimed |
| CN-114450284-A | 6, 7-dihydro-5H-pyrido [2,3-C ] pyridazine derivatives and related compounds as BCL-XL protein inhibitors and pro-apoptotic agents for the treatment of cancer | 法国施维雅药厂 | 2022-05-06 | — | — | CN | claimed |
| US-11319306-B2 | Compositions and methods for treating neurodegenerative diseases | AZEVAN PHARMACEUTICALS, INC. (US) | 2022-05-03 | — | — | US | claimed |
| US-20220112187-A1 | PYRAZOLOPYRIDINE AMINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | HOFFMANN-LA ROCHE INC. (US) | 2022-04-14 | — | — | US | claimed |
| WO-1996031214-A1 | 2-ACYLAMINOPROPANAMIDES AS TACHYKININ RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 1996-10-10 | — | — | WO | claimed |
| EP-0321122-B1 | Water soluble camptothecin analogs | SMITHKLINE BEECHAM CORP (US) | 1996-09-25 | — | — | EP | claimed |
| EP-0714891-A1 | Heterocyclic tachykinin receptor antagonists | ELI LILLY AND COMPANY (US) | 1996-06-05 | — | — | EP | claimed |
| WO-1996008480-A1 | NEUROKININ ANTAGONISTS | BOEHRINGER INGELHEIM KG (DE) | 1996-03-21 | — | — | WO | claimed |
| US-5215967-A | AMINOACID DERIVATIVES INHIBITING RENIN | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1993-06-01 | — | — | US | claimed |
| US-5004758-A | Water soluble camptothecin analogs useful for inhibiting the growth of animal tumor cells | SMITHKLINE BEECHAM CORPORATION (US) | 1991-04-02 | — | — | US | claimed |
| EP-0103465-B1 | 20-AMINO MACROLIDE DERIVATIVES | ELI LILLY AND COMPANY (US) | 1986-09-10 | — | — | EP | claimed |
| EP-0103465-A1 | 20-Amino macrolide derivatives | ELI LILLY AND COMPANY (US) | 1984-03-21 | — | — | EP | claimed |
| US-3951982-A | Trialkylsilyl esters of 6(substituted amino)phenyl-1,-dihydro-2-oxonicotinic acid, methods for their production and conversion to the corresponding acid chlorides | PARKE, DAVIS & COMPANY | 1976-04-20 | — | — | US | claimed |
| US-3946015-A | Process for the preparation of acid chlorides | PARKE, DAVIS & COMPANY (US) | 1976-03-23 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220112187-A1 | PYRAZOLOPYRIDINE AMINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | SSB, KCNJ1, KCNJ11 | L3MBTL3 4227/4885L3MBTL1 4082/4885MBTD1 3399/4885 |
| US-20240115553-A1 | COMPOSITIONS AND METHODS FOR TREATING BRAIN INJURY | FABP7, PYGB, CHAT | L3MBTL3 1989/4885L3MBTL1 3725/4885MBTD1 4152/4885 |
| US-11319306-B2 | Compositions and methods for treating neurodegenerative diseases | HTT, AVPR2, AVPR1B | L3MBTL3 4543/4885L3MBTL1 4451/4885MBTD1 3355/4885 |
| US-11639352-B2 | Benzothiazole compounds for the treatment of autoimmune diseases | SSB, BET1, HLA-DRB1 | L3MBTL3 3426/4885L3MBTL1 2157/4885MBTD1 434/4885 |
| US-11591299-B1 | Prodrug compound of levosimendan, preparation method and use thereof | CYP2D6, CYP21A2, CYP2B6 | L3MBTL3 3490/4885L3MBTL1 4159/4885MBTD1 3137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.